Trial site
Azienda Sanitaria Locale Della Provincia Di Biella
Ponderano, 13875, ItalyNot linked to an institution yet
- 20running trials
- 5closed trials
The trials here
What the 25 trials at this site are about, from their registry records.
- Phase
- Phase 318 trials
- Phase 25 trials
- Phase 2/32 trials
- Status
- Recruiting11 trials
- Active, not recruiting8 trials
- Completed5 trials
- Not yet recruiting1 trial
- Lead sponsor
- Fondazione Italiana Linfomi - ETS3 trials
- Daiichi Sankyo2 trials
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS2 trials
- Praxis Precision Medicines Inc.2 trials
- ARCAGY/ GINECO GROUP1 trial
- and 15 more
Running trials
Recruiting
PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)
2025-521666-10-01· Phase 2· Fondazione Italiana Linfomi Ets· Source
Recruiting
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.
2025-521640-38-00· Phase 3· Praxis Precision Medicines Inc.· Source
Recruiting
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
NCT07022483· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
2024-517529-26-00· Phase 3· Dianthus Therapeutics Inc.· Source
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· Phase 3· AstraZeneca· Source
Not yet recruiting
A Study to Learn About the Study Medicine Called Aztreonam-Avibactam in Neonates and Infants Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Bacteria
NCT06462235· Phase 2· Pfizer Inc.· Source
Recruiting
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
NCT06897644· Phase 3· Gruppo Oncologico del Nord-Ovest· Source
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· Phase 3· Genmab· Source
Recruiting
The Sagittarius Trial
NCT06490536· Phase 3· IFOM ETS - The AIRC Institute of Molecular Oncology· Source
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Active, not recruiting
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547· Phase 3· ARCAGY/ GINECO GROUP· Source
Active, not recruiting
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
NCT05058404· Phase 3· Fondazione Italiana Linfomi - ETS· Source
Active, not recruiting
MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination.
2024-516632-99-00· Phase 2· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source
Active, not recruiting
Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO33)
2024-516649-38-00· Phase 3· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source
Recruiting
NeoAspMet - Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced rectal cancer. A multi-arm, multi-stage, intergroup (STAR-04/SICO-CR01/GISCAD/AIRO-GI) randomised clinical trial. The NeoAspMet trial
2024-519007-10-00· Phase 2/3· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Recruiting
Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients
2024-517200-10-00· Phase 2· Fondazione Ricerca Traslazionale· Source
Active, not recruiting
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
NCT03981796· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients
NCT02390869· Phase 3· Fondazione Italiana Linfomi - ETS· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error